Searchable abstracts of presentations at key conferences in endocrinology

ea0020p86 | Thyroid | ECE2009

A comprehensive surgical approach of persistent cervical papillary thyroid carcinoma based on initial surgery and modern preoperative imaging modalities

Benmiloud Fares , Taieb David , Sebag Frederic , Henry Jean-Francois

Context: Reoperative surgery is the most efficient treatment of cervical persistent thyroid carcinoma. The extent of the surgery should be guided by the preoperative imaging findings, the primary surgery and the patient’s prognosis. However, there is no consensus concerning the optimal surgical strategy.Objective: Primary objective was to evaluate morbidity of a reoperative surgery. Secondary objectives were to evaluate performances of preoperative ...

ea0063p410 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

Large adrenal incidentalomas require a dedicated diagnostic procedure

Amodru Vincent , Taieb David , Guerin Carole , Paladino Nuncia Cinzia , Brue Thierry , Sebag Frederic , Castinetti Frederic

Introduction: The management of large non secreting adrenal tumors (at least 4 cm) is still a matter of debate as it is unclear whether imaging, especially 18F-FDG, can be used to characterize their potential malignancy. Moreover, the risk of new hypersecretion in non-operated tumors is uncertain. Our aim was to better characterize these large adrenal incidentalomas.Methods: Patients followed in our Center for a non-secreting large (at least 4 cm) adrena...

ea0020p60 | Thyroid | ECE2009

The value of TSH-assisted 18F-FDG PET in initial stage M0 thyroid carcinoma with suspicion of residual or recurrent disease

Taieb David , Ghander Cecile , Sebag Frederic , Tessonnier Laurent , Palazzo F Fausto , De Micco Catherine , Henry Jean-Francois , Mundler Olivier

Purpose: Persistence of well-differentiated thyroid carcinoma most commonly involves cervical lymph nodes. The purposes of the study were to evaluate the ability of FDG-PET/CT imaging to localize residual disease in initial stage M0 thyroid carcinoma thyroid cancer patients and to compare FDG-PET/CT to neck US.Methods: FDG-PET/CT and neck US results of 93 patients were retrospectively analysed. All FDG-PET/CT were performed during thyrotropin stimulation...

ea0020p108 | Thyroid | ECE2009

Quality of life changes, clinical outcomes and radiation protection issues in thyroid cancer patients undergoing radioiodine remnant ablation with recombinant human thyrotropin: a randomized controlled study

David Taieb , Frederic Sebag , Maria Cherenko , Karine Baumstarck-Barrau , Farman-Ara Bardia , De Micco Catherine , Henry Jean Francois , Mundler Olivier

Background: Recombinant human TSH (rhTSH) has become the modality of choice for radioiodine remnant ablation of residual thyroid cancer tissue in low-risk patients.Methods: The FACIT-F was administered from the early postoperative period to 9 months. Socio-demographic parameters, anxiety and depression scales were also evaluated. At 24 h, 48 h and d6 post-therapy, dose rate were measured. Using a simplified model, radiation exposure to public was estimat...

ea0020p189 | Endocrine tumours and neoplasia | ECE2009

Tumor/liver standardized uptake values ratio <1.8 on FDG-PET has a high negative predicitive value to rule-out malignancy in patients with incidentally identified non-secreting adrenal tumours

Taieb David , Tessonnier Laurent , Sebag Frederic , Morange Isabelle , De Micco Catherine , Conte-Devolx Bernard , Henry Jean-Francois , Mundler Olivier

Purpose: The widespread use of high resolution cross-sectional imaging such as computer tomography (CT) and magnetic resonance imaging (MRI) for the investigation of the abdomen is associated with an increasing detection of incidental adrenal masses. 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) has proved to be an efficient tool in the diagnosis and follow-up of malignancies. We evaluated the ability of FDG-PET to distinguish benign from malignant adrenal mass...

ea0089c28 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2022

Diagnostic Performance of PET or PET/CT Utilizing 18F-DOPA, 68Ga-DOTATATE, 18F-FDG, 18F-FDA, and CT and MRI in the Detection of MEN2A-related-pheochromocytoma

Jha Abhishek , Patel Mayank , Ling Alexander , Chen Clara C. , Millo Corina , Charles Kailah , Talvacchio Sara , Ezemobi Josephine , Herscovitch Peter , Lin Frank I. , Nilubol Naris , Taieb David , Cahid Civelek Ali , Carrasquillo Jorge , Pacak Karel

Background: Pheochromocytoma (PHEO) is a rare neuroendocrine tumor arising from chromaffin cells of adrenal gland that can cause life-threatening complications due to overproduction of catecholamines. Per EANM/SNMMI 2019 guidelines for radionuclide imaging of PHEO and paraganglioma, 18F-fluoro-L-dihydroxyphenylalanine (18F-FDOPA) is recommended as a positron emission tomography (PET) radiotracer of choice followed by 68Ga-DOTA(0)-Tyr(3)-octreot...

ea0089c29 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2022

Diagnostic Performance of PET or PET/CT Utilizing 18F-DOPA, 68Ga-DOTATATE, 18F-FDG, 18F-FDA, and CT and MRI the Detection of VHL-related Pheochromocytoma

Jha Abhishek , Patel Mayank , Ling Alexander , Chen Clara C. , Millo Corina , Charles Kailah , Talvacchio Sara , Ezemobi Josephine , Herscovitch Peter , Lin Frank I. , Nilubol Naris , Taieb David , Cahid Civelek Ali , Carrasquillo Jorge , Pacak Karel

Background: The purpose of this prospective study was to evaluate and compare the detection rates of 18F-L-dihydroxyphenylalanine (18F-FDOPA), 68Ga-DOTATATE, 18F-FDG, and 18F-fluorodopamine (18F-FDA) PET or positron emission tomography/computed tomography (PET/CT), computed tomography (CT), and magnetic resonance imaging (MRI) in the detection of VHL-related pheochromocytoma (PHEO).<p class="abstext...

ea0089c27 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2022

Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT, CT, and MRI Spine in the Detection of Spinal Bone Metastases in Metastatic Pheochromocytoma/Paraganglioma

Jha Abhishek , Patel Mayank , Saboury Babak , Millo Corina , Ling Alexander , Shah Ritu , Chen Clara C. , Meuter Leah , Talvacchio Sara , Knue Marianne , Lin Frank I. , O'Sullivan Coyne Geraldine , Chen Alice P. , Nilubol Naris , Herscovitch Peter , Taieb David , Cahid Civelek Ali , Carrasquillo Jorge A. , Pacak Karel

Background: To evaluate and compare the diagnostic performance of 68Ga-DOTATATE PET/CT to 18F-FDG PET/CT, CT of neck, chest, abdomen and pelvis (CT), and MRI of cervical, thoracic, and lumbar spine (MRI spine), for the detection of spinal bone metastases in metastatic pheochromocytoma and/or paraganglioma (PPGL).Methods: Between 2014 and 2019, 41 consecutive metastatic PPGL patients (19 females; mean age, 43 years) underwent 68...

ea0098t5 | Trials In Progress | NANETS2023

Phase 3 LEVEL trial of 177Lu-edotreotide vs everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (GETNE-T2217)

Capdevila Jaume , Fazio Nicola , Alvarez Rosa , Ansquer Catherine , Baldari Sergio , Baudin Eric , Benavent Marta , Benini Lavinia , Beron Amandine , Berruti Alfredo , Cingarlini Sara , del Olmo-Garcia Maribel , Deshayes Emmanuel , Garcia-Alvarez Alejandro , Garcia-Carbonero Rocio , Haissaguerre Magalie , Hernando Jorge , Anido Herranz Urbano , Jimenez-Fonseca Paula , Lepage Come , Llana Belen , Molina-Cerrillo Javier , Panzuto Francesco , Pubul Virginia , Sansovini Maddalena , Tafuto Salvatore , Taieb David , Teule Alex , Versari Annibale , Villacampa Guillermo , Walter Thomas

Background: Everolimus is the only approved drug for patients with advanced bronchopulmonary neuroendocrine tumors (NET), and there is an urgent unmet need for alternative treatments. Retrospective data for peptide receptor radionuclide therapy (PRRT) have demonstrated promising activity in somatostatin receptor (SST)-positive lung NET. This study aims to investigate the clinical efficacy, safety, and patient-reported outcomes when 177Lu-edotreotide is used to treat...